腫瘍アブレーション市場：技術、治療、適応症別-2024-2030年の世界予測

腫瘍アブレーション市場規模は2023年に17億8,000万米ドルと推計され、2024年には20億1,000万米ドルに達し、CAGR 13.85%で2030年には44億2,000万米ドルに達すると予測されています。

腫瘍アブレーションは、体内の様々な器官内の腫瘍の治療に用いられる低侵襲手術法です。この治療法は、大きな切開を必要とせずにがん細胞を破壊するために、腫瘍に直接、熱、低温、または化学薬剤を作用させる。肝臓がん、腎臓がん、骨がん、肺がんなどの治療によく用いられています。しかし、大きな腫瘍や、重要な構造物や臓器に近い腫瘍に対しては、これらの部位を損傷する危険性があるため、この手法が常に有効とは限らないです。さらに、出血、感染、周辺組織の損傷などの合併症が起こる可能性もあります。このような懸念に対処するためには、アブレーション技術の精度の向上、手技をガイドするためのより優れた画像技術の開発、アブレーションを行う医療従事者のトレーニングの強化など、継続的な研究が必要です。人工知能と機械学習の進歩は、アブレーション手技の精度と結果の改善につながる可能性があります。さらに、世界のがんの有病率の増加と低侵襲治療に対する需要の高まりが、腫瘍アブレーションの採用を促進すると考えられます。

治療低侵襲手術を必要とする患者に対する腹腔鏡下アブレーションの急速な利用

腹腔鏡下焼灼術は、低侵襲の方法を用いて、高周波、マイクロ波、レーザーなどのさまざまなエネルギー源を用いて、皮膚の小さな切開口から腫瘍にアクセスし、破壊します。この方法は、回復が早く、低侵襲のオプションを必要とする患者に好まれます。小から中サイズの腫瘍の治療や、切除エネルギーの正確な適用が必要な場合に特に有利です。経皮的切除術では、CTスキャンや超音波などの画像診断技術によって誘導された針を皮膚から腫瘍に直接挿入します。最も一般的なタイプは高周波（RF）アブレーションとマイクロ波アブレーションです。この方法は、手術や腹腔鏡では届きにくい場所に腫瘍がある患者や、開腹手術の候補でない患者に好まれます。経皮的方法は低侵襲で、通常、従来の手術に比べて入院期間が短く、痛みも少ないです。外科的切除術は、開腹手術によって腫瘍を摘出した後、切除技術を適用して残存するがん細胞を除去します。この方法は主に、腫瘍が大きい場合や、腫瘍が他の切除方法では困難な位置にある場合に用いられます。外科的切除は、腫瘍の完全切除が可能で望ましい場合に好まれ、腫瘍が孤立していてアクセス可能な場合に治癒の可能性を提供します。また、腫瘍の大きさや位置により腹腔鏡や経皮的方法が実行不可能な場合にも選択されます。

適応：肺がんの治療に腫瘍アブレーションを使用する調査の増加

腫瘍アブレーション、特に冷凍アブレーションは、小さな早期乳がんの治療で有望視されています。この方法は、従来の手術に代わる侵襲の少ない治療法であり、回復に要する時間や美容的な影響を軽減できる可能性があります。しかし、その適用は通常小さな腫瘍に限られ、標準的な乳がん手術と比較した長期的な有効性はまだ調査中です。乳がん治療における腫瘍アブレーションの治療成績と潜在的な役割をよりよく理解するためには、継続的な臨床試験が不可欠です。小さな腎腫瘤に対しては、ラジオ波焼灼療法（RFA）やクライオアブレーションなどの腫瘍アブレーション法が効果的に用いられています。これらの方法は、他の健康上の問題から手術に適さない患者や、腫瘍が小さく限局している患者にとって特に有益です。腫瘍アブレーションは、原発性および続発性の肝がんの管理において確立された役割を担っています。RFAやマイクロ波焼灼療法（MWA）のような技術は、特に外科的切除が不可能な症例で一般的に使用されています。これらの方法は、局所腫瘍制御を達成するのに有効であり、潜在的な生存利益を提供し、良好な安全性プロファイルを持っています。腫瘍アブレーション、特にRFA、クライオアブレーション、MWAの使用は、非小細胞肺がん（NSCLC）の治療選択肢として台頭してきています。これらの技術は、早期肺がんや他の原発部位から肺への転移を管理するための低侵襲アプローチを提供します。腫瘍アブレーションは、限局性前立腺がんの治療において、クライオアブレーションやフォーカルレーザーアブレーション（FLA）などの方法が検討され、関心を集めています。これらの技術は、前立腺摘除術や放射線療法といった従来の治療法に伴う副作用、特に失禁や勃起不全を軽減することを目的とした、標的を絞ったアプローチを提供します。前立腺がんにおける腫瘍アブレーションの対象患者の選択には、腫瘍の大きさ、位置、侵襲性を慎重に考慮する必要があります。

地域別の洞察

南北アメリカでは、先進的な腫瘍アブレーション技術の採用率が高く、強力なヘルスケアインフラと有利な償還政策に支えられています。同地域には最先端のアブレーションデバイスを開発・製造する大手企業が存在し、世界市場シェアに大きく貢献しています。APAC地域では、医療費の増加、がん罹患率の上昇、患者や医療従事者の低侵襲治療に対する意識の高まりなどを背景に、腫瘍アブレーションの使用が急増しています。APACの生産能力は拡大しているが、市場はまだ欧米市場で普及している技術・規制基準に追いつく過程にあります。地元企業もいくつか台頭してきているが、地理的なプレゼンス拡大を目指す世界企業にとっても魅力的な市場です。EMEAには多様なシナリオがあり、西欧の先進的なヘルスケアシステムは、強固な規制の枠組みに反映された腫瘍アブレーション技術を採用するための強固な基盤を提供しています。EMEA地域に進出している企業には、世界企業もあれば、地域特有の中小企業もあり、複雑な規制状況や市場情勢を乗り越えて、腫瘍アブレーション療法を提供しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは腫瘍アブレーション市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、腫瘍アブレーション市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.腫瘍アブレーション市場の市場規模および予測は？

2.腫瘍アブレーション市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.腫瘍アブレーション市場の技術動向と規制枠組みは？

4.腫瘍アブレーション市場における主要ベンダーの市場シェアは？

5.腫瘍アブレーション市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん罹患率の上昇と効果的な治療法の必要性
    • 腫瘍を除去するための低侵襲手術への移行が増加
    • 進行がん治療の償還政策の改善
  • 抑制要因
    • 腫瘍アブレーションデバイス設計の複雑さ
  • 機会
    • 世界中で腫瘍アブレーション技術の進歩
    • 腫瘍アブレーションに対する政府の好意的な承認
  • 課題
    • デバイスの品質と安全性に関する懸念
• 市場セグメンテーション分析
  • 治療：低侵襲手術を必要とする患者に対する腹腔鏡下アブレーションの急速な普及
  • 適応症：肺がんの治療に腫瘍アブレーションを使用する調査の増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 腫瘍アブレーション市場：技術別

• 凍結療法
• 高密度焦点式超音波
• 不可逆的電気穿孔アブレーション
• レーザー組織内熱アブレーション
• マイクロ波アブレーション
• 高周波アブレーション

第7章 腫瘍アブレーション市場治療別

• 腹腔鏡下アブレーション
• 経皮アブレーション
• 外科的アブレーション

第8章 腫瘍アブレーション市場適応症別

• 乳がん
• 腎臓がん
• 肝臓がん
• 肺がん
• 前立腺がん

第9章 南北アメリカの腫瘍アブレーション市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の腫瘍アブレーション市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの腫瘍アブレーション市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • メドトロニック、FDA承認のOsteoCool 2.0システムで骨腫瘍治療を向上
  • BioTraceIOが超音波ベースのBioTraceIOでFDAの承認を取得
  • FDAがFrancis Medical, Inc.の水蒸気アブレーション療法のVanquishに画期的指定を付与
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. TUMOR ABLATION MARKET RESEARCH PROCESS
• FIGURE 2. TUMOR ABLATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TUMOR ABLATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. TUMOR ABLATION MARKET DYNAMICS
• FIGURE 7. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. TUMOR ABLATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. TUMOR ABLATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TUMOR ABLATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TUMOR ABLATION MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL TUMOR ABLATION MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL TUMOR ABLATION MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL TUMOR ABLATION MARKET SIZE, BY CRYOABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL TUMOR ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL TUMOR ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL TUMOR ABLATION MARKET SIZE, BY IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL TUMOR ABLATION MARKET SIZE, BY IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL TUMOR ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL ABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL TUMOR ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL ABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL TUMOR ABLATION MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL TUMOR ABLATION MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL TUMOR ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL TUMOR ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL TUMOR ABLATION MARKET SIZE, BY LAPAROSCOPIC ABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL TUMOR ABLATION MARKET SIZE, BY LAPAROSCOPIC ABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL TUMOR ABLATION MARKET SIZE, BY PERCUTANEOUS ABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL TUMOR ABLATION MARKET SIZE, BY PERCUTANEOUS ABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL TUMOR ABLATION MARKET SIZE, BY SURGICAL ABLATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL TUMOR ABLATION MARKET SIZE, BY SURGICAL ABLATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL TUMOR ABLATION MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL TUMOR ABLATION MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL TUMOR ABLATION MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL TUMOR ABLATION MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL TUMOR ABLATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL TUMOR ABLATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL TUMOR ABLATION MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL TUMOR ABLATION MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL TUMOR ABLATION MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL TUMOR ABLATION MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 49. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 50. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 55. BRAZIL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 56. BRAZIL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 57. BRAZIL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 58. BRAZIL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 59. BRAZIL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 60. BRAZIL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 61. CANADA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 62. CANADA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 63. CANADA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 64. CANADA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 65. CANADA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 66. CANADA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 67. MEXICO TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 68. MEXICO TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 69. MEXICO TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 70. MEXICO TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 71. MEXICO TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 72. MEXICO TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 73. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 74. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 75. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 76. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 77. UNITED STATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 78. UNITED STATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 79. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 80. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 82. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 84. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 86. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 88. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 89. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 90. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 91. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 92. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 93. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 94. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 95. CHINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 96. CHINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 97. CHINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 98. CHINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 99. CHINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. CHINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. INDIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 102. INDIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 103. INDIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 104. INDIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 105. INDIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 106. INDIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 107. INDONESIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 108. INDONESIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 109. INDONESIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 110. INDONESIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 111. INDONESIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 112. INDONESIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 113. JAPAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 114. JAPAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 115. JAPAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 116. JAPAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 117. JAPAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 118. JAPAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 119. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 120. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 121. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 122. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 123. MALAYSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 124. MALAYSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 125. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 126. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 127. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 128. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 129. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 130. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 131. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 132. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 133. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 134. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 135. SINGAPORE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 136. SINGAPORE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 137. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 138. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 139. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 140. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 142. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 143. TAIWAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 144. TAIWAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 145. TAIWAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 146. TAIWAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 147. TAIWAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 148. TAIWAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 149. THAILAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 150. THAILAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 151. THAILAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 152. THAILAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 153. THAILAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 154. THAILAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 155. VIETNAM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 156. VIETNAM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 157. VIETNAM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 158. VIETNAM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 159. VIETNAM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 160. VIETNAM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 169. DENMARK TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 170. DENMARK TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 171. DENMARK TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 172. DENMARK TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 173. DENMARK TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 174. DENMARK TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 175. EGYPT TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 176. EGYPT TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 177. EGYPT TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 178. EGYPT TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 179. EGYPT TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 180. EGYPT TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 181. FINLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 182. FINLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 183. FINLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 184. FINLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 185. FINLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 186. FINLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 187. FRANCE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 188. FRANCE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 189. FRANCE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 190. FRANCE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 191. FRANCE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 192. FRANCE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 193. GERMANY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 194. GERMANY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 195. GERMANY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 196. GERMANY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 197. GERMANY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 198. GERMANY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 199. ISRAEL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 200. ISRAEL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 201. ISRAEL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 202. ISRAEL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 203. ISRAEL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 204. ISRAEL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 205. ITALY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 206. ITALY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 207. ITALY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 208. ITALY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 209. ITALY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 210. ITALY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 211. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 212. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 213. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 214. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 215. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 216. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 217. NIGERIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 218. NIGERIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 219. NIGERIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 220. NIGERIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 221. NIGERIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 222. NIGERIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 223. NORWAY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 224. NORWAY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 225. NORWAY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 226. NORWAY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 227. NORWAY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 228. NORWAY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 229. POLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 230. POLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 231. POLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 232. POLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 233. POLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 234. POLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 235. QATAR TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 236. QATAR TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 237. QATAR TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 238. QATAR TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 239. QATAR TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 240. QATAR TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 241. RUSSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 242. RUSSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 243. RUSSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 244. RUSSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 245. RUSSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 246. RUSSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 247. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 248. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 249. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 250. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 251. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 252. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 259. SPAIN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 260. SPAIN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 261. SPAIN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 262. SPAIN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 263. SPAIN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 264. SPAIN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 265. SWEDEN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 266. SWEDEN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 267. SWEDEN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 268. SWEDEN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 269. SWEDEN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 270. SWEDEN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 271. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 272. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 273. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 274. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 275. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 276. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 277. TURKEY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 278. TURKEY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 279. TURKEY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 280. TURKEY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 281. TURKEY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 282. TURKEY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 283. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 284. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 285. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 286. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 287. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 288. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 289. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 290. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 291. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 292. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 293. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 294. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 295. TUMOR ABLATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 296. TUMOR ABLATION MARKET, FPNV POSITIONING MATRIX, 2023

[180 Pages Report] The Tumor Ablation Market size was estimated at USD 1.78 billion in 2023 and expected to reach USD 2.01 billion in 2024, at a CAGR 13.85% to reach USD 4.42 billion by 2030.

Tumor ablation is a minimally invasive surgical method used for the treatment of tumors within various organs of the body. This procedure involves directing heat, cold, or chemical agents directly into a tumor to destroy cancer cells without necessitating large incisions. It is commonly employed in the treatment of liver, kidney, bone, and lung cancers, among others. However, the technique may not always be effective for larger tumors or for tumors that are close to critical structures or organs, as there is a risk of damaging these areas. Additionally, there may be complications such as bleeding, infection, or damage to the surrounding tissues. Addressing these concerns involves ongoing research into improving the precision of ablation techniques, developing better imaging technology to guide the procedures, and enhancing the training of medical professionals performing ablations. Advances in artificial intelligence and machine learning could lead to improved precision and outcomes of ablation procedures. Furthermore, the increasing prevalence of cancer worldwide and the rising demand for minimally invasive treatments are likely to drive the adoption of tumor ablation.

Treatment: Exponential use of laparoscopic ablation for patients requiring minimally invasive surgery

Laparoscopic ablation involves the use of minimally invasive methods to access and destroy tumors using various energy sources, such as radiofrequency, microwave, or laser, through small incisions in the skin. This method is preferred for patients who require a minimally invasive option with a quicker recovery time. It is particularly advantageous for treating small to medium-sized tumors and where a precise application of ablation energy is needed. Percutaneous ablation involves the insertion of needles through the skin directly into the tumor, guided by imaging techniques such as CT scans or ultrasound. The most common types include radiofrequency (RF) ablation and microwave ablation. This approach is preferred for patients with tumors in locations difficult to reach by surgery or laparoscopy or who are not candidates for open surgery. The percutaneous method is minimally invasive and usually involves a shorter hospital stay and less pain compared to traditional surgery. Surgical Ablation entails the removal of the tumor through open surgery, followed by the application of ablation techniques to eliminate any remaining cancer cells. This method is primarily used for larger tumors or when tumors are located in positions that make other forms of ablation challenging. Surgical ablation is preferred when complete tumor resection is possible and desirable, offering a potential cure in cases where tumors are isolated and accessible. It is also chosen in situations where laparoscopic or percutaneous methods are not feasible due to the size or location of the tumor.

Indication: Increasing research in using tumor ablation for treating lung cancer

Tumor ablation, particularly cryoablation, has shown promise in the treatment of small, early-stage breast cancers. This method offers a less invasive alternative to traditional surgery, potentially reducing recovery times and cosmetic impact. However, its application is usually limited to small tumors, and the long-term efficacy compared to standard breast cancer surgeries is still under research. Ongoing clinical trials are essential to better understand the outcomes and potential roles of tumor ablation in breast cancer treatment. For small renal masses, tumor ablation techniques such as radiofrequency ablation (RFA) and cryoablation have been effectively used. These methods are particularly beneficial for patients who are not suitable for surgery due to other health concerns or for those with small, localized tumors. Tumor ablation has a well-established role in the management of primary and secondary liver cancers. Techniques such as RFA and microwave ablation (MWA) are commonly used, especially in cases where surgical resection is not possible. These methods can be effective in achieving local tumor control, offer potential survival benefits, and have a favorable safety profile. The use of tumor ablation, specifically RFA, cryoablation, and MWA, is emerging as a treatment option for non-small cell lung cancer (NSCLC). These techniques offer a minimally invasive approach to manage early-stage lung cancers or metastases to the lungs from other primary sites. Tumor ablation is gaining interest in the treatment of localized prostate cancer, with methods such as cryoablation and focal laser ablation (FLA) being explored. These techniques provide a targeted approach that aims to reduce side effects associated with more traditional treatments like prostatectomy and radiation therapy, particularly incontinence and erectile dysfunction. The selection of patients for tumor ablation in prostate cancer requires careful consideration of tumor size, location, and aggressiveness.

Regional Insights

In the Americas, there is a high adoption rate of advanced tumor ablation technologies, supported by strong healthcare infrastructure and favorable reimbursement policies. The region is home to leading companies that develop and manufacture cutting-edge ablation devices, contributing significantly to the global market share. The APAC region is witnessing rapid growth in the use of tumor ablation, driven by increasing healthcare expenditure, rising cancer prevalence, and growing awareness of minimally invasive treatments among patients and healthcare providers. Although APAC's production capabilities are expanding, the market is still in the process of catching up to the technical and regulatory standards prevalent in Western markets. Several local players are emerging, but the market is also attractive for global companies looking to expand their geographic presence. EMEA presents a diverse scenario where advanced healthcare systems in Western Europe offer a solid ground for the adoption of tumor ablation technologies mirrored by robust regulatory frameworks. Companies operating in the EMEA region are a mix of established global players and smaller, region-specific companies navigating the complex regulatory and market landscape to ensure the availability of tumor ablation therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Tumor Ablation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Tumor Ablation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Tumor Ablation Market, highlighting leading vendors and their innovative profiles. These include Angiodynamics, Inc., Bioventus LLC., Boston Scientific Corp., BVM Medical Limited, Chongqing Haifu Medical Technology Co., Ltd., CONMED Corporation, CooperSurgical, Inc., Erbe Elektromedizin GmbH, IceCure Medical Ltd., Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Mermaid Medical A / S, Smith & Nephew PLC, and Theraclion S. A..

Market Segmentation & Coverage

This research report categorizes the Tumor Ablation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Cryoablation
  • High-Intensity Focused Ultrasound
  • Irreversible Electroporation Ablation
  • Laser Interstitial Thermal Ablation
  • Microwave Ablation
  • Radiofrequency Ablation

• Treatment
  • Laparoscopic Ablation
  • Percutaneous Ablation
  • Surgical Ablation

• Indication
  • Breast Cancer
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Prostate Cancer

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Tumor Ablation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Tumor Ablation Market?

3. What are the technology trends and regulatory frameworks in the Tumor Ablation Market?

4. What is the market share of the leading vendors in the Tumor Ablation Market?

5. Which modes and strategic moves are suitable for entering the Tumor Ablation Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer and need for effective treatments
    • 5.1.1.2. Increasing shift to minimally invasive surgeries to remove tumors
    • 5.1.1.3. Improvements in reimbursement policies for advanced cancer treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity of designing tumor ablation devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in tumor ablation technologies worldwide
    • 5.1.3.2. Favorable government approvals for tumor ablation
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with quality and safety of the device
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Exponential use of laparoscopic ablation for patients requiring minimally invasive surgery
  • 5.2.2. Indication: Increasing research in using tumor ablation for treating lung cancer
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Tumor Ablation Market, by Technology

• 6.1. Introduction
• 6.2. Cryoablation
• 6.3. High-Intensity Focused Ultrasound
• 6.4. Irreversible Electroporation Ablation
• 6.5. Laser Interstitial Thermal Ablation
• 6.6. Microwave Ablation
• 6.7. Radiofrequency Ablation

7. Tumor Ablation Market, by Treatment

• 7.1. Introduction
• 7.2. Laparoscopic Ablation
• 7.3. Percutaneous Ablation
• 7.4. Surgical Ablation

8. Tumor Ablation Market, by Indication

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Kidney Cancer
• 8.4. Liver Cancer
• 8.5. Lung Cancer
• 8.6. Prostate Cancer

9. Americas Tumor Ablation Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Tumor Ablation Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Tumor Ablation Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Medtronic Elevates Bone Tumor Treatment with FDA-Approved OsteoCool 2.0 System
  • 12.3.2. BioTraceIO receives FDA Approval for Ultrasound-Based BioTraceIO
  • 12.3.3. FDA Grants Breakthrough Designation to Vanquish Water Vapor Ablation Therapy by Francis Medical, Inc.
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio